Article Text

other Versions

Download PDFPDF
Actions required to assure continuous supply of anti-rheumatic medication during the SARS-CoV-2/COVID-19 pandemic. Response to: ‘Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience’ by Pineda-Sic et al
  1. Hendrik Schulze-Koops1,
  2. Klaus Krueger2,
  3. Christof Specker3
  4. On behalf of the Kommission Pharmakotherapie of the German Society of Rheumatology
  1. 1 Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig-Maximilians-Universitat Munich, Munich, Bayern, Germany
  2. 2 Praxiszentrum St Bonifatius, Munich, Germany
  3. 3 Klinik für Rheumatologie und Klinische Immunologie, KEM Kliniken Essen-Mitte, Essen, Germany
  1. Correspondence to Professor Hendrik Schulze-Koops, Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig-Maximilians-Universitat Munich, Munich 80336, Bayern, Germany; hendrik.schulze-koops{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

With great interest but also some concerns we read the study of Dr Pineda-Sic et al 1 on treatment adherence of patients with inflammatory rheumatic diseases (IRD) during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 pandemic in Latin America. In an anonymous electronic survey of consecutive patients at the rheumatology outpatient clinic of the university hospital in Monterrey, Mexico, the authors requested information about treatment adherence from patients with IRD. From the 345 patients who responded between 14 and 25 May 2020, 293 (85%) had not changed their medication. Importantly, 91.3% of all patients indicated that they knew about the benefits of their treatment.

These data are reassuring, as current guidelines, for example by the German Society of Rheumatology (DGRh eV),2 the European League Against Rheumatism3 or the American College of Rheumatology,4 …

View Full Text


  • Handling editor Josef S Smolen

  • Contributors HS-K, KK and CS wrote and revised the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles